Company intelligence / Profile preview

Neuboron Medtech

Nanjing, Jiangsu, Chinaen.neuboron.com ↗

Ownership: Private
Development stage: Other

Overview

Neuboron's AB-BNCT technology has been used to treat patients under clinical trial settings since October 2022. The NeuPEX Block-I system demonstrates high performance in beam utilization efficiency and treatment depth. Their BPA boron drug shows promise for lower toxicity compared to Japanese products.

Therapeutic areas: Oncology
Modalities: DeviceSmall moleculeNanoparticleMonoclonal antibodyLiposome-based drug delivery therapyRadiopharmaceutical
Industry: Biotech

Partnerships

TAE Life Sciences (joint venture partner)Yantai Dongcheng Pharmaceutical GroupShanghai Renji HospitalXiamen Humanity Hospital & C&D GroupCNAO/INFN Italy

Beyond the preview

Go deeper on Neuboron Medtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuboron Medtech.

Explore the full profile